Back to results
US 11,142,795 B2Granted
Methods of treating viral infection
AssigneeAcademia Sinica
InventorsShie-Liang Hsieh, Ya-Lang Huang, Tsung-Yu Tsai
Life of this patent
Estimating the term…
Abstract
Disclosed herein is a novel use of C-type lectin 18 (CLEC18) in disease prognosis. According to embodiments of the present disclosure, the mRNA or protein level of CLEC18 may serve as an indicator for diagnosing hepatitis B virus (HBV) infection, hepatitis B e antigen (HBeAg) loss and seroconversion, and/or liver fibrosis.
Claims3
A method of diagnosing and treating severe liver fibrosis in a subject having chronic hepatitis B, comprising,
- (a) isolating a biological sample from the subject;
- (b) measuring the protein level of CLEC18 in the biological sample;
- (c) determining the severity of liver fibrosis in the subject based on the measured protein level of CLEC18 in step (b), wherein
- when the protein level of CLEC18 is lower than 320 pg/mL, then the subject has severe liver fibrosis;
- and
- (d) administering to the subject having severe liver fibrosis as determined in the step (c) a treatment selected from the group consisting of, interferon (IFN), lamivudine, adefovir, entecavir, telbivudine, and tenofovir.
3 more elements
Dependencies are inferred from the claim text.